25 min listen
CureVac disappoints in COVID vaccine trial
FromNature Podcast
ratings:
Length:
13 minutes
Released:
Jun 18, 2021
Format:
Podcast episode
Description
After a slew of wildly successful vaccine trials, this week marked a more underwhelming result. The third mRNA vaccine to complete phase three trials, developed by CureVac, is just 47% effective at staving off disease according to preliminary data. This is a stark contrast with previous mRNA vaccines from Moderna and Pfizer BioNtec which returned around twice that efficacy in their trials. In this episode of Coronapod, we ask why the CureVac vaccine has faltered, and what this might mean for the future of the pandemic and mRNA vaccine development.News: CureVac COVID vaccine let-down spotlights mRNA design challengesNews Feature: How COVID unlocked the power of RNA vaccinesSubscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.
See acast.com/privacy for privacy and opt-out information.
See acast.com/privacy for privacy and opt-out information.
Released:
Jun 18, 2021
Format:
Podcast episode
Titles in the series (100)
Nature Podcast: 23 April 2015: This week, a new treatment for Ebola, the making of the Tibetan plateau, and could bees be addicted to pesticides? by Nature Podcast